Novo Nordisk, fighting competition to its blockbuster Victoza, just posted data on a follow-up drug that gives it an edge over archrival Trulicity.

Valeant says the situation is looking up at that Bausch + Lomb plant that has twice been responsible for Valeant receiving a CRL for a new eye drug.

If you’re looking for certainty in immuno-oncology, Bristol-Myers’ latest Opdivo-plus-Yervoy data won't help.

Biocon, which pulled its EU application for a Herceptin biosimilar because of manufacturing issues, expects to resubmit to authorities next quarter.

Facebook is the social media platform most pharma marketers plan to use in the next two years, followed by YouTube, LinkedIn and Twitter.

How do you get 100% of the payers you approach to cover a pricey new med? Mitsubishi Tanabe’s commercial chief has an idea.

With a Soliris biosimilar showing up in its rearview mirror, Alexion is piling on patents for its superexpensive drug.

Should the FDA cut down drug-risk statements in TV ads? The not-surprising finding of a new agency study—short lists are easier to recall—suggests so.